GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » 5-Year Yield-on-Cost %

SILO (SILO Pharma) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 13, 2024)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma 5-Year Yield-on-Cost %?

SILO Pharma's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for SILO Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:



SILO's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of SILO Pharma's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, SILO Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where SILO Pharma's 5-Year Yield-on-Cost % falls into.



SILO Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of SILO Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

SILO Pharma  (NAS:SILO) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


SILO Pharma 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of SILO Pharma's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma Business Description

Traded in Other Exchanges
N/A
Address
677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797